Advertisement

Cancer Immunology, Immunotherapy

, Volume 32, Issue 4, pp 235–240 | Cite as

The influence of anti-(ricin toxin A chain) monoclonal antibodies on the pharmacokinetics of ricin toxin A chain and recombinant ricin A chain in mice

  • M. V. Pimm
  • B. Gunn
  • J. M. Lord
  • R. W. Baldwin
Original articles

Summary

Two monoclonal antibodies against ricin toxin A chain (RTA) have been examined for their effects on the blood survival and biodistribution of RTA and recombinant ricin A chain in mice. When admixed with the toxins at 1:1 molar ratios prior to intravenous injection, the antibodies prolonged blood survival and whole-body retention of both species of RTA, and this was due essentially to reduced renal clearance of the toxins. Immune complexes were identified by gel filtration chromatography and immune precipitation with anti-IgG antiserum in mixtures prior to injection and in the serum of mice injected with the mixtures. An irrelevant monoclonal antibody showed no complex formation, and no effect on biodistribution. These studies have shown that immune complexes formed between monoclonal antibodies and protein antigens of molecular mass up to at least 30 kDa survive in the circulation, rather than being cleared by the reticuloendothelial system. Such antibodies could be used to modulate the biodistribution of toxic molecules such as ribosome-inhibiting proteins like RTA. This might be exploited therapeutically, for example in the construction of bispecific antibodies against ribosomal inhibiting proteins and tumour-associated antigens.

Keywords

Monoclonal Antibody Immune Complex Renal Clearance Inhibit Protein Protein Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Corvalan JRF, Smith W, Gore VA, Brandon DR (1987) Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids. Cancer Immunol Immunother 24: 133Google Scholar
  2. 2.
    Corvalan JRF, Smith W, Gore VA (1988) Tumour therapy with vinca alkaloids targeted-by a hybrid-hybrid monoclonal antibody recognising both CEA and vinca alkaloids. Int J Cancer [Suppl]2: 22Google Scholar
  3. 3.
    Fraker PJ, Speck JC Jr (1978) Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a, 6a-diphenylglycoluril. Biochem Biophys Res Commun 80: 849Google Scholar
  4. 4.
    Fulton RI, Blakey DC, Knowles PP, Uhr JW, Thorpe PE, Vitetta ES (1986) Purification of ricin A1, A2 and B chains and characterisation of their toxicity. J Biol Chem 261: 5314Google Scholar
  5. 5.
    Glennie MJ, Brennand DM, Bryden F, McBride HM, Stirpe F, Worth AT, Stevenson GT (1988) Bispecific F(ab′)2 antibody for delivery of saporin in the treatment of lymphoma. J Immunol 141: 3622Google Scholar
  6. 6.
    Mannik M, Arend WP (1971) Fate of preformed immune complexes in rabbits and rhesus monkeys. J Exp Med 134: 19 sGoogle Scholar
  7. 7.
    O'Hare M, Roberts LM, Thorpe PE, Watson GJ, Prior B, Lord MJ (1987) Expression of ricin A chain inEscherichia coli. FEBS Lett 216: 73Google Scholar
  8. 8.
    Pimm MV, Caten JE, Clegg JA, Jacobs E, Baldwin RW (1987) Comparative biodistribution of methotrexate and monoclonal antibody-metorexate complexes in mice. J Pharm Pharmacol 39: 764Google Scholar
  9. 9.
    Pimm MV, Clegg JA, Baldwin RW (1987) Biodistribution and tumour localization of radiolabelled monoclonal antibody during continuous infusion in nude mice with human tumour xenografts. Eur J Cancer Clin Oncol 23: 521Google Scholar
  10. 10.
    Price MR, Edwards S, Jacobs E, Pawluczyk IZA, Byers VS, Baldwin RW (1987) Mapping of monoclonal antibody-defined epitopes associated with carcinoembryonic antigen, CEA. Cancer Immunol Immunother 25: 10Google Scholar
  11. 11.
    Robins RA, Embleton MJ, Pimm MV, Betts DS, Charleston A, Markham AJ, Baldwin RW (1990) Bispecific antibody which binds carcinoembryonic antigen and ricin toxin A chain is cytotoxic for gastrointestinal tract tumour cells. J Natl Cancer Inst 82: 1295Google Scholar
  12. 12.
    Rosenblum MG, Unger BW, Gutterman JU, Hersh EM, David GS, Frincke JM (1985) Modification of human leukocyte interferon pharmacology with a monoclonal antibody. Cancer Res 45: 2421Google Scholar
  13. 13.
    Rosenblum MG, Murray JL, Stuckey S, Newman RA, Chaney S, Khokhar AR (1990) Modification of methyliminodiacetato-trans-R,R-1,2-diamminocyclohexane platinum (II) pharmacology using a platinum-specific monoclonal antibody. Cancer Chemother Pharmacol 25: 405Google Scholar
  14. 14.
    Rowland M, Tozer TN (1989) Clinical pharmacokinetics, 2nd edn. Lea and Fibiger, Philadelphia, pp 459–63Google Scholar
  15. 15.
    Skilleter DN, Price RJ, Thorpe PE (1985) Modification of the carbohydrate in ricin with metaperiodate and cyanoborohydride mixtures: effect on binding, uptake and toxicity to parenchymal and nonparenchymal cells of rat liver. Biochim, Biophys, Acta 842: 12Google Scholar
  16. 16.
    Stewart MW, Petty RE (1972) The use of ammonium sulphate globulin precipitation for determination of affinity of anti-protein antibodies in mouse serum. Immunology 22: 747Google Scholar
  17. 17.
    Stirpe F, Barbieri L (1986) Ribosome-inactivating proteins up to date. FEBS Lett 195: 1Google Scholar
  18. 18.
    Zalcberg JR (1985) Monoclonal antibodies to drugs: novel diagnostic and therapeutic reagents. Pharmacol Ther 28: 273Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • M. V. Pimm
    • 1
  • B. Gunn
    • 1
  • J. M. Lord
    • 2
  • R. W. Baldwin
    • 1
  1. 1.Cancer Research Campaign LaboratoriesUniversity of NottinghamNottinghamUK
  2. 2.Department of Biological SciencesUniversity of WarwickCoventryUK

Personalised recommendations